Drugs / AL-611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03253471 | Jul → Sep 2017 | chronic hepatitis C virus infection | Alios Biopharma Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL-611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03253471 ↗ |
| Route | Oral | “orally administered AL-611” NCT03253471 ↗ |